News
Zacks.com on MSN22h
Ultragenyx Pharmaceuticals Gets CRL for UX111 Gene Therapy for MPS IIIARARE faces regulatory setback as FDA issues a CRL for UX111, delaying approval of the MPS IIIA gene therapy until 2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback